Lenvatinib and pembrolizumab in patients with metastatic papillary renal cell carcinoma: A phase 2 pilot study.

被引：0
|
作者：
Tsimafeyeu, Ilya [1 ]
Sultanbaev Sr, Alexander [2 ]
Vilkov, Sergey
机构：
[1] Republican Clin Oncol Dispensary, Ufa, Russia
[2] Hadassah Med, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
109
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [31] Real-world efficacy and safety of lenvatinib plus pembrolizumab in metastatic renal cell carcinoma patients with intermediate and poor risk
    Tsimafeyeu, I.
    Sultanbaev, A. V.
    Dubovichenko, D. M.
    Murzalina, M.
    Volkov, A.
    Orlova, R. V.
    Malina, G.
    Utyashev, I.
    Gluzman, M. I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1519 - S1519
  • [32] Treatment outcome for metastatic papillary renal cell carcinoma patients
    Rormen, Ellen A.
    Kondagunta, G. Varuni
    Ishill, Nicole
    Spodek, Lesley
    Russo, Paul
    Reuter, Victor
    Bacik, Jennifer
    Motzer, Robert J.
    CANCER, 2006, 107 (11) : 2617 - 2621
  • [33] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2021, 206 (06) : 1518 - 1519
  • [34] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [35] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Nacev, Benjamin Alexander
    Rosenbaum, Evan
    Thornton, Katherine Anne
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Qin, Li-Xuan
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Meyers, Paul A.
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    Qin, Li-Xuan
    Salcito, Tiffany
    Seier, Kenneth
    Tap, William D.
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma
    Grande, E.
    Glen, H.
    Aller, J.
    Argenziano, G.
    Lamas, M. J.
    Ruszniewski, P.
    Zamorano, J. L.
    Edmonds, K.
    Sarker, S.
    Staehler, M.
    Larkin, J.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1413 - 1426
  • [38] Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Ren, Min
    Dutcus, Corina
    Larkin, James
    LANCET ONCOLOGY, 2016, 17 (01) : E4 - E5
  • [39] Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma
    Lee, Chung-Han
    DiNatale, Renzo G.
    Chowell, Diego
    Krishna, Chriag
    Makarov, Vladimir
    Shapnik, Natalie
    Murray, Samuel J.
    Carlo, Maria Isabel
    Voss, Martin H.
    Feldman, Darren R.
    Hakimi, A. Ari
    Adachi, Yusuke
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    Perini, Rodolfo F.
    Nomoto, Kenichi
    Motzer, Robert J.
    Chan, Timothy An-thy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
    Motzer, Robert J.
    Choueiri, Toni K.
    Hutson, Thomas
    Rha, Sun Young
    Puente, Javier
    Lalani, Aly-Khan A.
    Winquist, Eric
    Eto, Masatoshi
    Basappa, Naveen S.
    Tannir, Nizar M.
    Vaishampayan, Ulka
    Bjarnason, Georg A.
    Oudard, Stephane
    Gruenwald, Viktor
    Burgents, Joseph
    Xie, Ran
    McKenzie, Jodi
    Powles, Thomas
    EUROPEAN UROLOGY, 2024, 86 (01) : 4 - 9
12345